Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Comment by zxcon Apr 20, 2001 2:10pm

207 Views

Post# 3636352

RE: Interesting analysis

For newbies...https://www.conac-ir.com/s/FinancialStatements-2001.asp?ReportID=21421 At this price,a short synopsis of CONAC is appropriate.$ happy investing all.

Bullboard Posts

B2Gold stock buckles under news of labour strike in Mali